0001178913-18-000718.txt : 20180228 0001178913-18-000718.hdr.sgml : 20180228 20180228160514 ACCESSION NUMBER: 0001178913-18-000718 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180227 FILED AS OF DATE: 20180228 DATE AS OF CHANGE: 20180228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Elliott Russell P. CENTRAL INDEX KEY: 0001727807 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36621 FILM NUMBER: 18651091 MAIL ADDRESS: STREET 1: C/O FOAMIX PHARMACEUTICALS LTD. STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 FORMER NAME: FORMER CONFORMED NAME: Russell Elliot DATE OF NAME CHANGE: 20180112 FORMER NAME: FORMER CONFORMED NAME: Elliot Russel DATE OF NAME CHANGE: 20180110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001606645 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 BUSINESS PHONE: 97289316233 MAIL ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 FORMER COMPANY: FORMER CONFORMED NAME: Foamix Ltd. DATE OF NAME CHANGE: 20140428 4 1 zk1821305.xml OWNERSHIP DOCUMENT X0306 4 2018-02-27 0 0001606645 Foamix Pharmaceuticals Ltd. FOMX 0001727807 Elliott Russell P. C/O FOAMIX PHARMACEUTICALS LTD. 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK REHOVOT L3 7670402 ISRAEL 0 1 0 0 VP Drug Development Ordinary Shares 2018-02-27 4 A 0 8750 0.00 A 13685 D Options 6.35 2018-02-27 4 A 0 26250 6.35 A 2028-02-27 Ordinary Shares 26250 26250 D This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. Each option represents a contingent right to purchase one ordinary share of the issuer. The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. /s/ Ilan Hadar as attorney-in-fact for Russell Elliott 2018-02-28